Guide
Oncology & Hematology

Immune Checkpoint Inhibitor Therapy: Optimize Dose and Patient Selection to Maximize Efficacy and Access

Since the approval of ipilimumab in 2011 for metastatic melanoma, immune checkpoint inhibitors (ICI) have shifted the treatment paradigm in oncology. Now increasingly indicated as first-line treatment of certain metastatic cancers, ICIs can trigger deep, durable responses and offer significant survival benefit. However, the majority of patients do not respond and many epeirence immune-related adverse events (irAEs).

As researchers seek to improve the efficacy and safety of ICIs and expand the application of these immunotherapies to broader patient populations, a critical area of study is dosing optimization. The goal of dosing optimization is to maximize therapeutic efficacy and access while minimizing toxicity and cost.

Continue this conversation with a Premier expert

Learn more about our strategic capabilities.